Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.crphar.2021.100056 http://scihub22266oqcxt.onion/10.1016/j.crphar.2021.100056 C8444447!8444447 !34870154     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34870154 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Curr+Res+Pharmacol+Drug+Discov 2021 ; 2 (?): 100056 Nephropedia Template TP {{tp|p=34870154 |t=2021. Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients |pdf=|usr=}}{{34870154 }} gab.com Text Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients JO: Curr Res Pharmacol Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=34870154 #FOAvip The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of ?brotic tissue. Even among cured individuals, the presence of pulmonary fibrotic tissue may be the major cause of long-term complications of COVID-19 requiring antifibrotic therapeutic treatment even in the post-COVID-19 infection phase to accelerate the healing process and fully recover lung function. This article reviews the fibrogenic mechanism of SARS-CoV-2-induced viral damage and the antifibrotic treatments indicated to treat sequelae post COVID-19 infection. Twit Text FOAVip Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients ????Curr Res Pharmacol Drug Discov http://www.kidney.de/pget.php?&tw=1&pmid=34870154 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34870154 #FOAvip English Wikipedia <ref>{{Cite pmid|34870154 }}</ref> Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients #MMPMID34870154 Vitiello A ; Ferrara F Curr Res Pharmacol Drug Discov 2021[]; 2 (?): 100056 PMID34870154 show ga The COVID-19 global pandemic has caused about 4,30 Mln deaths. Recently the first vaccines have been licensed, representing the most powerful weapon available to stop the pandemic. The COVID-19 viral infection in the most severe cases can cause severe lung lesions with the presence of ?brotic tissue. Even among cured individuals, the presence of pulmonary fibrotic tissue may be the major cause of long-term complications of COVID-19 requiring antifibrotic therapeutic treatment even in the post-COVID-19 infection phase to accelerate the healing process and fully recover lung function. This article reviews the fibrogenic mechanism of SARS-CoV-2-induced viral damage and the antifibrotic treatments indicated to treat sequelae post COVID-19 infection. ?Physiopathology and prospectives for therapeutic treatment of pulmonar(epmc).pdf DeepDyve Pubget Overpricing